Vontobel Holding Ltd. Acquires New Holdings in CEL-SCI Co. (NYSE:CVM)

Vontobel Holding Ltd. acquired a new stake in shares of CEL-SCI Co. (NYSE:CVM) in the 4th quarter, HoldingsChannel reports. The institutional investor acquired 25,000 shares of the company’s stock, valued at approximately $68,000.

Other hedge funds also recently bought and sold shares of the company. Cutter & CO Brokerage Inc. grew its stake in CEL-SCI by 20.5% in the 3rd quarter. Cutter & CO Brokerage Inc. now owns 102,845 shares of the company’s stock worth $129,000 after buying an additional 17,500 shares in the last quarter. Lincoln National Corp grew its stake in CEL-SCI by 138.2% in the 3rd quarter. Lincoln National Corp now owns 55,545 shares of the company’s stock worth $69,000 after buying an additional 32,225 shares in the last quarter. Finally, Black Diamond Financial LLC grew its stake in CEL-SCI by 20.5% in the 3rd quarter. Black Diamond Financial LLC now owns 53,000 shares of the company’s stock worth $66,000 after buying an additional 9,000 shares in the last quarter. Hedge funds and other institutional investors own 12.08% of the company’s stock.

Analyst Ratings Changes

Separately, StockNews.com cut shares of CEL-SCI from a “hold” rating to a “sell” rating in a research note on Friday, March 15th.

CEL-SCI Price Performance

CVM stock opened at $1.45 on Thursday. The company has a debt-to-equity ratio of 0.75, a current ratio of 1.26 and a quick ratio of 0.78. CEL-SCI Co. has a one year low of $1.04 and a one year high of $3.23. The stock has a market cap of $78.27 million, a PE ratio of -2.13 and a beta of 1.29. The firm has a 50 day simple moving average of $1.95 and a two-hundred day simple moving average of $2.19.

CEL-SCI (NYSE:CVM) last announced its quarterly earnings data on Wednesday, February 14th. The company reported ($0.14) earnings per share for the quarter. On average, analysts predict that CEL-SCI Co. will post -0.51 EPS for the current fiscal year.

CEL-SCI Profile

CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research and development of immune system therapy for the treatment of cancer and other diseases in the United States. The company's lead immunotherapy is Multikine, which has completed Phase 3 clinical trials for the potential treatment of certain head and neck cancers.